Table 2.
Patient Characteristics
| Characteristics | Control (n=42)a | Aprepitant (n=46)b | p Value |
|---|---|---|---|
| Gender (%) | |||
| Male | 24 (57.1) | 28 (60.9) | 0.723 |
| Female | 18 (42.9) | 18 (39.1) | |
| Age | |||
| Median, yr (range) | 47 (22–68) | 53 (22–69) | 0.224 |
| Diagnosis (%) | |||
| Acute myeloblastic leukemia | 17 (40.5) | 18 (39.1) | |
| Acute lymphoblastic leukemia | 4 (9.5) | 3 (6.5) | |
| Adult T-cell leukemia/lymphoma | 8 (19.0) | 6 (13.0) | |
| Malignant lymphoma | 4 (9.5) | 11 (23.9) | |
| Myelodysplastic syndrome | 5 (11.9) | 3 (6.5) | |
| Other | 4 (9.5) | 5 (10.9) | |
| Conditioning regimen (%) | |||
| Myeloablative regimens | 22 (52.4) | 20 (43.5) | 0.404 |
| TBI/CY | 13 (31.0) | 12 (26.1) | |
| BU/CY | 4 (9.5) | 2 (4.3) | |
| Flu/BU4 | 5 (11.9) | 6 (13.0) | |
| Nonmyeloablative regimens | 20 (47.6) | 26 (56.5) | |
| Flu/BU2 | 6 (14.3) | 12 (26.1) | |
| Flu/CY | 3 (7.1) | 1 (2.2) | |
| Flu/MEL/TBI | 11 (26.2) | 13 (28.3) | |
| Sources of stem cells (%) | |||
| Related donor | 16 (38.1) | 14 (30.4) | 0.504 |
| PB | 10 (23.8) | 11 (23.9) | |
| BM | 6 (14.3) | 3 (6.5) | |
| Unrelated donor | 26 (61.9) | 32 (69.6) | |
| BM | 10 (23.8) | 23 (50.0) | |
| CB | 16 (38.1) | 9 (19.6) | |
TBI = total body irradiation; CY = cyclophosphamide, BU = busulfan; Flu = fludarabine; MEL = melphalan; PB = peripheral blood stem cell transplantation; BM = bone marrow transplantation; CB = cord blood stem cell transplantation.
a
Patients in the control group received granisetron alone as an antiemetic.
b
Patients in the aprepitant group received aprepitant and granisetron as antiemetics.